You are here

  • Home
  • Archive
  • Volume 83, Issue Suppl 1
  • POS0260 ONCE-MONTHLY SEL-212 DEMONSTRATES EFFICACY AND SAFETY FOR UP TO 6-MONTHS IN GOUT REFRACTORY TO CONVENTIONAL THERAPY: COMBINED DATA FROM THE DISSOLVE I & II PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIALS

Citation Tools

Article menu
Download PDFPDF
Scientific Abstracts
Poster Tours
Clinical Poster Tours: Gout treatment in 2024
POS0260 ONCE-MONTHLY SEL-212 DEMONSTRATES EFFICACY AND SAFETY FOR UP TO 6-MONTHS IN GOUT REFRACTORY TO CONVENTIONAL THERAPY: COMBINED DATA FROM THE DISSOLVE I & II PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIALS

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Baraf HSB, Khanna P, Patel A, et al
POS0260 ONCE-MONTHLY SEL-212 DEMONSTRATES EFFICACY AND SAFETY FOR UP TO 6-MONTHS IN GOUT REFRACTORY TO CONVENTIONAL THERAPY: COMBINED DATA FROM THE DISSOLVE I & II PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIALS
Annals of the Rheumatic Diseases 2024;83:408-409.